Skip to content

SBIR Phase 3 Commercialization Guide (2026)

Updated 15 official sources

Quick Answer: SBIR Phase 3 isn't a grant you apply for. It's follow-on work paid with non-SBIR money: federal contracts, product sales, or licensing.

Full answer and how we checked it

Agencies obligated $9.35 billion on contracts coded SBIR or STTR Phase III in FY2024 and FY2025, and the Department of Defense funded 90.4% of it. Agencies can award it sole-source, with no dollar cap and no deadline.

Who this is for: If you're a small technology business with an SBIR or STTR Phase I or Phase II award and you want to turn it into revenue, start here. It's also useful for first-time applicants who want to see where the SBIR program actually leads before they write a Phase I proposal.

Data note: Phase III dollar figures on this page come from Grantsights analysis of public contract records in the Federal Procurement Data System (FPDS) (opens in a new tab), pulled October 20, 2026. FPDS is the source for contract data on USAspending.gov (opens in a new tab). Figures are net obligations, so they count deobligations against new money.

Source review by Grantsights, October 20, 2026: Grantsights checked section 4(c) of the SBA SBIR/STTR Policy Directive (opens in a new tab) (effective May 3, 2023), the April 13, 2026 reauthorization law (P.L. 119-83 (opens in a new tab)), GAO's 2025 Digital Force Technologies protest decision (opens in a new tab), and FPDS contract records. Where official sources stop: Phase III isn't a new grant round. It's work that derives from, extends, or completes prior SBIR/STTR work and is paid with non-SBIR funds. Grantsights analysis of 10,770 contract actions coded SBIR or STTR Phase III in FY2024 and FY2025 found $9.35 billion in net obligations. The Department of Defense funded 90.4% of it, while the Department of Health and Human Services, which includes NIH, funded $5.7 million, or 0.06%. Method: Grantsights pulled every FPDS action with research code SR3 (SBIR Phase III) or ST3 (STTR Phase III) signed October 1, 2023 through September 30, 2025, removed duplicate records, and summed obligated dollars by funding department and competition code. That's why a company asking for a "Phase III grant" is a bad fit, and so is a firm chasing a sole-source contract without a derivation memo, a customer owner, an acquisition path, and a budget source. For example, the Air Force's Phase III contract with Bluestaq LLC of Colorado Springs, Colorado, cites a 2018 Phase I contract (FA9453-18-P-0230) and showed $580.4 million in total obligations on USAspending.gov (opens in a new tab) on October 20, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Check official source
Status
Upcoming

Assistance Listing 93.395: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.395, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
3,308
Avg Award (whole listing)
$3,837,757
Median Award (whole listing)
$1,827,310
Total Funding (FY2024, whole listing)
$1.1B
YoY Funding Trend
+1.2%

Data last verified: April 8, 2026

Most SBIR guides (including our own complete SBIR grants guide) spend most of their ink on Phase I and Phase II applications and barely mention Phase III. That's a mistake. Phase III is where the SBIR program either delivers real value or fizzles out. It's also where the program's most powerful feature, sole-source contracting authority, lives. If you don't understand Phase III when you start your SBIR journey, you'll miss opportunities to position yourself during Phase I and Phase II.

What SBIR Phase 3 Actually Is

Section 4(c) of the SBA Policy Directive defines Phase III as work that "derives from, extends, or completes" an effort made under prior SBIR/STTR funding agreements but is funded by sources other than the SBIR/STTR programs. In practice, that covers:

  • Commercial sales of products or services based on the SBIR technology
  • Follow-on government contracts that continue, expand, or apply the SBIR work
  • Licensing agreements where another entity pays to use the technology
  • Joint ventures or partnerships that commercialize the technology
  • Production contracts for the government to purchase the developed technology

The defining characteristic of Phase III: no SBIR set-aside money is involved. Funding comes from the agency's regular procurement budget, from commercial customers, or from other non-SBIR government programs. The directive's federal rules cover only the government-funded side. Private deals, such as a license to a device maker, count as commercialization but aren't federal Phase III awards unless they're a subcontract under a federal contract.

Phase III AttributeDetails
Funding sourceAgency procurement budgets, commercial revenue, non-SBIR programs
Dollar limitNone (Policy Directive 4(c)(5))
Time limit on authorityNone; no limit on the time between a Phase I or II award and Phase III
Application processNo standard application; initiated by contracting officer or commercial deal
Competition requiredNo, though an agency may still compete the work (about a third of FY2024-2025 Phase III dollars carried a competed code in FPDS)
Size limitNone; Phase I and II size limits don't apply (4(c)(6))
Data rightsSBIR/STTR data rights apply, with a protection period of at least 20 years from award
Available toAny SBIR/STTR Phase I or Phase II awardee

Sole-Source Authority: SBIR's Most Powerful Feature

The SBIR Phase III sole-source authority is one of the most underappreciated features of the entire SBIR program. Here's what it means practically.

Under the Federal Acquisition Regulation (FAR), contracts above the simplified acquisition threshold, now $350,000 under FAR 2.101 (opens in a new tab), generally require full and open competition. The government has to post a solicitation, evaluate multiple bidders, and award to the best value offer, which can take many months.

SBIR Phase III bypasses all of that.

A contracting officer can award a Phase III contract to your company without competition, without posting a solicitation, and without evaluating other bidders. The justification is short by design. According to section 4(c)(3) of the SBA Policy Directive (opens in a new tab), the Phase I and Phase II competitions already satisfy the Competition in Contracting Act, so if an agency wants a Justification and Approval, it's enough to state that the work is an SBIR/STTR Phase III award that derives from, extends, or completes prior SBIR/STTR work under 15 U.S.C. 638(r)(4). "Further justification is not needed," the directive says.

The data shows how often agencies use it. Grantsights analysis of FPDS records found that 67.8% of the $9.35 billion in FY2024-2025 Phase III obligations was coded "not available for competition" or "not competed," most of it under the statutory-authority exception in FAR 6.302-5. Another 23.4% was coded as competed among small businesses only, and 8.7% as competed under full and open or simplified procedures. Sole-source is the norm, not a guarantee.

What Sole-Source Authority Covers

The contract must be for work that "derives from, extends, or completes" your SBIR-funded effort. GAO has read that test in the work's favor. In Digital Force Technologies, Inc., B-423319 (opens in a new tab) (May 19, 2025), GAO denied a protest of an Air Force Phase III award to Clear Align, holding that the test applies to the work being bought, not the agency's requirement, and that one SBIR-derived component, a camera, was enough when it was reasonably related to the system the Air Force wanted. Phase III authority covers:

  • Production and manufacturing of the technology you developed
  • Further development or enhancement of the technology
  • Integration of the technology into a larger system
  • Services related to the technology (maintenance, training, deployment)
  • Applications of the technology to new problems within the agency's mission

What Sole-Source Authority Does NOT Cover

Phase III authority doesn't give you a blank check for any contract with the government. The work must have a clear connection to your prior SBIR effort. If the contracting officer can't draw a line between the Phase III contract and your SBIR research, the authority doesn't apply. Competitors can (and do) protest Phase III awards at GAO, arguing the work isn't sufficiently related to the original SBIR. Digital Force Technologies did exactly that in 2025 and lost because the Air Force could show the SBIR lineage of the camera at the center of Clear Align's system.

No Dollar Limit, No Time Limit

There's no cap on Phase III contract value, and section 4(c)(5) of the directive says there's no limit on the number, duration, type, or dollar value of Phase III awards, or on the time between a Phase I or Phase II award and a Phase III award. Bluestaq's Air Force Phase III, which grew from a 2018 Phase I contract, showed $580.4 million in total obligations on USAspending.gov (opens in a new tab). Most Phase III awards are far smaller, though. The median new Phase III base award in FPDS for FY2024-2025 started with $450,000 in obligations, across 1,868 new awards with money attached.

The legal window doesn't close, but the practical one narrows. The longer it's been since your SBIR work, the more the technology has changed and the harder it gets to show the Phase III work still derives from it. Keep your SBIR deliverables, contract numbers, and topic numbers in one place so a contracting officer can trace the line years later.


How SBIR Phase 3 Works at DOD

DOD is where Phase III contracting authority gets used most. Grantsights analysis of FPDS records found that DOD funded $8.45 billion of the $9.35 billion in FY2024-2025 Phase III obligations, or 90.4%, and 1,548 of the 1,875 new Phase III base awards. Here's why: DOD has a specific, persistent need for technology that works in military environments, and the normal path from a written requirement to a fielded system can take years, which is too slow for fast-changing threats.

The Technology Transition Gap

DOD calls it the "valley of death": the gap between a successful SBIR Phase II demonstration and a production contract or program of record. Your Phase II prototype works in a lab, but getting it into the hands of warfighters requires manufacturing, testing, integration, training, and logistics support that Phase II funding doesn't cover.

Phase III contracts bridge this gap. A program manager who likes your Phase II results can use sole-source authority to fund additional development, engineering for production, low-rate initial production, or full-rate production.

When the real bottleneck is manufacturing capacity or supplier resilience rather than another prototype step, DOD may also route work through DPA Title III expansion funding. That path is worth checking if your Phase III story depends on scaling domestic production.

Where the Phase III Money Went in FY2024 and FY2025

Funding agencyFY2024 Phase III obligationsFY2025 Phase III obligationsShare of FY2024-2025 total
Department of Defense (all components)$4.05 billion$4.40 billion90.4%
Department of Homeland Security$153.5 million$206.3 million3.9%
NASA$87.0 million$238.6 million3.5%
Department of Veterans Affairs$44.1 million$59.8 million1.1%
Health and Human Services (includes NIH)$1.5 million$4.2 million0.06%
All agencies$4.36 billion$4.99 billion100%

Source: Grantsights analysis of FPDS contract actions with research code SR3 or ST3, net obligations by funding department, pulled October 20, 2026. About $2.15 billion of the DOD total was contracted through GSA's Federal Acquisition Service on DOD's behalf.

Inside DOD, the Air Force and Navy dominate. Contracts run by the Department of the Air Force carried $1.20 billion in FY2024 and $1.57 billion in FY2025, and Navy contracts carried $1.03 billion and $1.36 billion. Army contracts carried $290.3 million and $236.0 million. Three named examples show what these awards look like:

  • Maritime Applied Physics Corporation of Baltimore, Maryland, holds Navy contract N00024-22-C-2228 for the GARC unmanned surface vessel, coded SBIR Phase III and not competed, with $315.6 million in total obligations on USAspending.gov (opens in a new tab).
  • Castelion Corporation of El Segundo, California, received Air Force contract FA8612-24-C-B010, coded STTR Phase III, for low-cost long-range strike weapon production. It was signed September 23, 2024 with $15.7 million obligated and reached $55.8 million after a $40.0 million modification on September 27, 2025, according to USAspending.gov (opens in a new tab).
  • Anduril Industries received $307.7 million in FY2025 Phase III obligations. Navy and Air Force contracts carried $152.6 million of it, including a Navy order for Altius-600M loitering munitions, and $148.5 million came from U.S. Customs and Border Protection tower orders, which makes CBP one of the few large civilian Phase III buyers.

DOD Phase III in Practice

Here's how it typically plays out at DOD:

  1. During Phase II, you demonstrate your technology to the end users (not just the SBIR program office, but the actual program of record that would buy it).
  2. Late in Phase II, you work with a program office to identify a requirement your technology addresses.
  3. The program office writes a sole-source justification citing your SBIR Phase I/II awards and the connection between your technology and their requirement.
  4. The contracting officer issues a Phase III contract using procurement funds (not SBIR set-aside money).

AFWERX and Rapid Capability Offices

The Air Force's AFWERX and similar DOD innovation organizations have streamlined Phase III transitions. AFWERX specifically uses a "Strategic Funding Increase" (STRATFI) model that blends SBIR Phase II funding with non-SBIR government and commercial capital. This helps bridge the transition gap with larger awards, which AFWERX's PY25.1 STRATFI briefing (opens in a new tab) lists at $3 million to $15 million, during the period between Phase II and full production.

For the full picture of SBIR at DOD versus other agencies, see the SBIR agencies comparison.


How Phase 3 Works at Civilian Agencies

Phase III looks different at civilian agencies because the end goal is usually commercial products rather than government procurement. The contract data makes the point. Grantsights analysis of FPDS records found that HHS, which includes NIH, funded $5.7 million in Phase III contract obligations across FY2024 and FY2025, NSF funded $4.4 million, and DOE funded about $1.0 million. NASA ($325.7 million) and Homeland Security ($359.8 million) were the only civilian buyers above $150 million. If your SBIR came from NIH or NSF, plan on a commercial customer, a licensee, or an investor, not a federal contract.

NIH Phase III

At NIH, Phase III typically means:

  • FDA-cleared or approved products generating commercial revenue
  • Technology licensed to pharmaceutical or medical device companies
  • Continued development funded by venture capital or strategic partners
  • Products adopted into clinical practice

NIH tracks commercialization through annual reporting requirements. The timeline is long, because drugs and devices need an FDA pathway before they can earn revenue. NIH has offered a Commercialization Readiness Pilot (CRP) for Phase II awardees, and P.L. 119-83 extended the civilian-agency CRP pilot authority through September 30, 2031. But NIH expired its SBIR/STTR NOFOs early during the lapse (NOT-OD-26-006 (opens in a new tab), released November 17, 2025), so check Grants.gov for a current CRP notice before you plan around it.

NSF Phase III

NSF's commercialization expectations focus on:

  • Revenue from commercial product sales
  • Follow-on private investment (venture capital, strategic investors)
  • Licensing deals with larger companies
  • Successful exits (acquisitions) based on the technology

NSF's I-Corps program, which many SBIR applicants participate in, specifically trains teams in customer discovery and commercial strategy. NSF Phase III success often looks like a startup that raised venture funding and launched a commercial product, with SBIR providing the initial non-dilutive capital that de-risked the technology.

DOE Phase III

DOE commercialization often involves:

  • Technology licensing to energy companies
  • Deployment through utility partnerships
  • Manufacturing scale-up with private capital
  • Government procurement for federal facilities

How to Position for Phase 3 During Phase II

The companies that achieve Phase III outcomes don't wait until their Phase II ends to start thinking about commercialization. The 2026 reauthorization pushes agencies the same way. P.L. 119-83 (opens in a new tab) gives SBA 1 year to revise the Policy Directive so agencies advocate for "the maximum practicable use and transition" of SBIR technology to Phase III, tells agencies to develop simplified procedures and model contracts for Phase I, II, and III awards, and requires Phase III training for contracting officers that covers data rights and sole-source awards. Here's what the companies that get there do differently.

Build Relationships with End Users Early

If your customer is a government agency, identify the program office or end user during Phase I. During Phase II, demonstrate your technology to them. Get their feedback. Incorporate their requirements. By the time Phase II ends, the program office should already want your technology and understand that Phase III authority makes it easy to buy.

Document the Connection Between SBIR and Phase III

Contracting officers need a paper trail to justify sole-source Phase III awards. Make it easy for them:

  • Keep detailed records of what you developed under each SBIR phase
  • Clearly show how Phase III work derives from your SBIR research
  • Prepare a sole-source justification document (even if the CO writes the official one, having a draft helps)
  • Reference your SBIR contract numbers in all communications. P.L. 119-83 now directs GSA to update FPDS so contracting officers record the prior SBIR or STTR contract number when they log a Phase III award, so have those numbers ready

Engage with Commercialization Assistance Programs

Several agencies offer formal assistance:

ProgramAgencyWhat It Provides
Commercialization Readiness Pilot (CRP)NIHSupplemental Phase II funding for commercialization activities (confirm a current notice is open)
Phase IIB supplement (opens in a new tab)NSFRequests up to $500,000; NSF matches up to 50% of qualifying third-party funds; requests above $250,000 need a formal financial package
Commercialization Readiness Program (CRP)DODTransition support; P.L. 119-83 adds a mechanism for direct access to program and requirements offices that may buy under Phase III
STRATFIAir Force (AFWERX)$3M-$15M per award, matched with non-SBIR government or private funds

Don't Neglect Your Commercialization Plan

Your Phase II proposal includes a commercialization plan. Reviewers read it, and it affects your score. But more importantly, a well-researched commercialization plan is your roadmap for Phase III. It should include specific customer targets, a realistic regulatory pathway (if applicable), a pricing strategy, and a timeline for revenue generation.

For help writing the commercialization section of your Phase II proposal, see our SBIR Phase 2 guide.


Success Metrics Agencies Track

Agencies don't just hand out SBIR money and forget about it. They track outcomes, and your commercialization performance affects future applications.

The SBA Commercialization Benchmark

Under the rule posted on SBIR.gov (opens in a new tab) as of October 13, 2026, the Commercialization Rate Benchmark applies once a company has received 16 or more Phase II awards (that is, more than 15) during the past ten fiscal years, excluding the two most recently completed fiscal years. Those companies must show minimum sales, investment, or patent results per Phase II award, with higher standards since April 1, 2023 for companies with 51 or more and 101 or more Phase II awards. A company that falls short loses eligibility for new Phase I awards for a period.

SBA has proposed replacing it. A notice published September 2, 2026 (FR Doc. 2026-17987) (opens in a new tab), with comments due October 31, 2026, would instead apply a minimum share of revenue from sources other than SBIR/STTR funding to companies with more than 25 Phase II awards in the five most recently completed fiscal years, and it names November 15, 2026 as the start date. SBIR.gov hadn't posted the new standard when Grantsights checked, so confirm which rule applies before you plan a Phase I submission.

Neither version touches most companies, since both start only after more than 15 or 25 Phase II awards, but both signal what the program values: commercial outcomes, not perpetual research.

What Agencies Report to Congress

SBA's annual report to Congress tracks:

  • Total Phase III funding (contracts and commercial revenue)
  • Number of patents resulting from SBIR research
  • Number of companies achieving commercial sales
  • Jobs created or retained at SBIR-funded companies
  • Follow-on investment attracted

These metrics shape policy. If SBIR's commercialization numbers look weak, Congress asks tough questions during reauthorization. This is why agencies increasingly emphasize commercialization potential during Phase I and Phase II review. If you're just starting out, our first-time applicant guide covers how to build commercialization thinking into your very first proposal.


The SBIR Program Lapse Nobody Planned For and What It Actually Means for Phase III

The SBIR/STTR program lapse that took effect October 1, 2025 disrupted Phase I and Phase II, and it raised a fair question about Phase III. The statutory authorization for SBIR and STTR expired on September 30, 2025, and new solicitations halted. NIH's NOT-OD-26-006 (opens in a new tab) expired all of its SBIR and STTR funding opportunities and said NIH wouldn't issue noncompeting continuation awards until reauthorization. Congress passed the Small Business Innovation and Economic Security Act (S. 3971) in March 2026, and it was signed into law on April 13, 2026 as P.L. 119-83 (opens in a new tab), reauthorizing SBIR and STTR through September 30, 2031.

Phase III didn't stop, because it never used SBIR set-aside money. Grantsights analysis of FPDS records found 2,152 Phase III contract actions with $2.31 billion in net obligations signed between October 1, 2025 and April 13, 2026, including 235 new base awards. In the same stretch a year earlier, agencies signed 2,367 actions and 297 new base awards. The biggest single lapse-period action was a $363.0 million CBP order for Anduril towers on December 18, 2025. New awards slowed, then, but they didn't freeze. A red flag for anyone whose Phase III request stalled during the lapse: don't assume it's still moving. Re-send the justification and your SBIR award record to the contracting officer now that the programs are authorized again.

Don't assume sole-source authority is self-executing. Contracting officers can use Phase III authority without agency-level SBIR program involvement, and many do. But a contracting officer who isn't familiar with SBIR Phase III procedures, especially at civilian agencies outside DOD, may want internal sign-off first. Your job is to educate the contracting officer directly. Prepare a one-page memo citing 15 U.S.C. 638(r)(4) and section 4(c) of the Policy Directive, your SBIR contract and topic numbers, and a written description of how the Phase III work derives from the prior SBIR effort. Don't wait for the contracting officer to figure this out. Bring the documentation to the first conversation.

Castelion Corporation shows how a Phase III pipeline builds. Its Air Force STTR Phase III contract (FA8612-24-C-B010) started with $15.7 million on September 23, 2024. Castelion's own company timeline says AFWERX selected it for STRATFI in March 2025, and the Air Force added $40.0 million to the Phase III contract on September 27, 2025, bringing it to $55.8 million. A second buyer followed: as of October 20, 2026, FPDS showed two FY2026 Navy orders to Castelion coded SBIR Phase III, worth $178.4 million combined. The sequence matters. STRATFI awards are matched with non-SBIR government or private money, so both the Phase III growth and the STRATFI selection depended on buyers and investors that already wanted the technology.

One practical issue that catches Phase II companies off guard: the sole-source justification you write isn't just legal documentation. It's a sales document. The contracting officer has to sign it, their supervisor has to review it, and the agency's legal counsel may review it. A protest from a competitor will be adjudicated against the written record. A justification that describes the Phase III work in general terms is harder to defend than one that traces each technical element back to specific Phase I and Phase II deliverables, so write the memo with a possible protest in mind from the start.


What the SBA Annual Report Doesn't Tell You

The official SBIR commercialization data paints a rosier picture of Phase III outcomes than the contract record supports. Here are the gaps.

Self-reported data is hard to check. Commercialization figures on SBIR.gov come from companies reporting their own sales and investment, and those totals mix commercial revenue, follow-on contracts, and investment capital. Treat any single headline rate with caution.

The federal contract record is only as good as its coding. The one federal record of Phase III contracts is the FPDS research code, and contracting officers set it by hand. Grantsights analysis of the 10,770 FY2024-2025 actions coded SR3 or ST3 found 17 actions whose product codes were janitorial or landscaping services, which are almost certainly miscoded. Congress noticed the gap too: section 8 of P.L. 119-83 (opens in a new tab) directs GSA to update FPDS so contracting officers designate Phase III prime and subcontract awards and record the prior SBIR or STTR contract number. Until that's in place, Phase III subcontracts under large primes are mostly invisible.

Phase III dollars are concentrated. In FY2025, the top 10 recipient names in FPDS took 30.3% of the $4.99 billion in Phase III obligations, while about 700 recipient names shared the rest. Large companies show up too, since the Policy Directive's size limits don't apply to Phase III: General Dynamics Mission Systems received $264.5 million in FY2025 Phase III obligations, almost all of it on Navy contracts. A first Phase III award for a small firm usually looks more like the $450,000 median new award than like these totals.

The timeline gap is hidden. Official reports show cumulative commercialization from all awards ever made. They don't break out how long it takes for a typical Phase II award to produce Phase III outcomes. A common mistake is to plan cash flow as if Phase III follows the last Phase II invoice. Budget for a gap, and expect a longer one for regulated products like drugs and medical devices, which need an FDA pathway before they earn revenue.

Survival rates aren't tracked well. Agencies know how many companies receive Phase II awards. There's no official count of how many are still in business 5 years later, and companies that close don't report outcomes.

Phase III depends on the 2 steps before it, so start with the guide for the phase you're in:


Sources

Largest awards active in FY2024

One row per recipient, its largest award | 3,308 Assistance Listing records | Avg: $3.8M

REAL DATA
1

Public Health Institute

CA

$333.7M
2

Sloan-Kettering Institute for Cancer Research

NY

$250.8M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Frequently Asked Questions

Is SBIR Phase 3 a grant?

No. Phase III is not a grant and doesn't come from SBIR set-aside funds. It refers to the commercialization stage where you bring SBIR-funded technology to market. This can happen through commercial product sales, federal contracts, licensing deals, or follow-on government funding from non-SBIR sources. For DOD, Phase III often means a production contract or a contract to further develop and integrate the technology into a program of record. The funding comes from the agency's regular procurement budget, not the SBIR budget. Grantsights analysis of federal contract records found $9.35 billion obligated on contract actions coded SBIR or STTR Phase III in FY2024 and FY2025, and 90.4% of it came from the Department of Defense.

How does SBIR Phase 3 sole-source authority work?

Federal agencies can award Phase III contracts to SBIR awardees without full and open competition. This means a contracting officer can give you a contract based on your SBIR work without going through the standard competitive bidding process. The sole-source authority applies to any work that derives from, extends, or completes an effort under a prior SBIR Phase I or Phase II award. There's no dollar limit on Phase III contracts. Under section 4(c)(7) of the SBA Policy Directive, if the agency finds the original awardee available, capable, and willing, it must award the Phase III work to that firm without competition. This authority exists to protect the government's investment in SBIR-funded R&D and to prevent larger contractors from capturing the technology you developed.

How long does SBIR Phase 3 sole-source authority last?

There's no statutory time limit on Phase III sole-source authority. It doesn't expire when your Phase II ends or after a certain number of years. As long as the work derives from your SBIR research, the authority remains available. The SBA Policy Directive says there's no limit on the time that may elapse between a Phase I or Phase II award and a Phase III award. For example, the Air Force's Phase III contract with Bluestaq LLC cites a 2018 Phase I contract, FA9453-18-P-0230, and it was still adding options in 2026. Contracting officers may still push back if the link to the original SBIR work has become hard to show, so keep the paper trail current.

What percentage of SBIR Phase II awardees get Phase III funding?

Grantsights couldn't verify a single official percentage. SBIR.gov collects commercialization data that companies report themselves, and those figures mix commercial sales, follow-on government contracts, and investment, so treat any one headline rate with caution. At DOD, the path is shorter for companies that actively engage with program offices during Phase II. At NIH, commercialization often takes longer because medical products require FDA regulatory pathways. The companies that successfully transition typically start building customer relationships during Phase II rather than waiting until the award ends.

Can I apply for SBIR Phase 3?

You don't apply for Phase III the way you apply for Phase I or Phase II. There's no standard solicitation or proposal format. Phase III happens through normal business channels: a federal contracting officer issues a contract using sole-source authority, a commercial customer places an order, or a licensee pays royalties. Your job is to make Phase III happen by building relationships with end users, demonstrating your technology's readiness, and helping contracting officers understand that sole-source authority applies. Some agencies have formal transition programs that help connect Phase II awardees with acquisition programs.

Did the 2025-2026 SBIR lapse stop Phase III contracts?

No. SBIR and STTR authority lapsed on October 1, 2025 and P.L. 119-83 reauthorized both programs on April 13, 2026 through September 30, 2031. Phase III doesn't use SBIR set-aside money, and federal contract records show agencies kept awarding it: Grantsights analysis of FPDS records found 2,152 Phase III contract actions and $2.31 billion in net obligations signed during the lapse, including 235 new base awards. That was fewer new awards than the 297 in the same stretch a year earlier, so expect some delay, but a stalled Phase III request during the lapse was not a legal dead end.

Last updated October 20, 2026. Corrected October 20, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.